54results about How to "Inhibit binding" patented technology

The invention provides a monoclonal antibody 6G2 resisting DENV NS1 protein and application of the monoclonal antibody 6G2. The CDR amino acid sequence of a heavy chain of the monoclonal antibody 6G2 resisting the DENV NS1 protein is shown as SEQ ID No.1, and the CDR amino acid sequence of a light chain of the monoclonal antibody 6G2 resisting the DENV NS1 protein is shown as SEQ ID No.3. The invention also provides application of the monoclonal antibody 6G2 to preparation of drugs for treating dengue virus infection, and the monoclonal antibody 6G2 for resisting DENV NS1 protein has the performances of competitively binding DENV1-4NS1 protein, inhibiting vascular leakage symptoms and protecting DENV infected fatal injury in vivo, and has potential important value for treating severe dengue fever. The monoclonal antibody 6G2 developed by the invention has important significance and application potential for prevention and treatment of dengue virus infection, including severe dengue fever.

The invention discloses combined lactobacillus salivarius CCFM1398 for regulating and controlling bone homeostasis and relieving bone resorption and a metagen of the combined lactobacillus salivarius CCFM1398, and belongs to the technical field of microorganisms. The combined lactobacillus salivarius CCFM1398 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that expression of protein level and gene level of MC3T3-E1 cell osteoprotegerin (OPG) is improved in vitro; the bone absorption amount of orthodontic bone absorption rat alveolar bone is reduced, the number of alveolar bone osteoclasts is reduced, and the level of rat serum OPG is improved; the secretion of inflammatory factors TNF-alpha, IL-6 and MPO of the orthodontic bone absorption rat is reduced; and the pathological condition of orthodontic bone absorption rat alveolar bone tissue is improved. Therefore, the combined lactobacillus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The invention belongs to the technical field of biology, and particularly relates to a PD-L1 targeting micromolecule polypeptide and application thereof. On the basis of machine learning and virtual screening technologies, a series of PD-L1 targeting micromolecule polypeptides are screened out, the in-vivo and in-vitro biological activities of the polypeptides are measured, it is found that the micromolecule polypeptides have the capacity of inducing PD-L1 to form dimerization and good anti-tumor activity, and the anti-tumor activity of the polypeptides is superior to that of PD-L1 monoclonal antibodies and compound inhibitors. Meanwhile, the PD-L1 targeting small-molecule polypeptide has no obvious toxicity, has certain safety, and can be developed into a novel small-molecule polypeptide PD-L1 inhibitor drug.

The invention discloses a combined lactobacillus salivarius CCFM1397 for improving osteoblast activity and relieving bone resorption and periodontal tissue damage and a metagen thereof, and belongs to the technical field of microorganisms. The lactobacillus salivarius combination CCFM1397 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that: the expression of MC3T3-E1 cell osteoprotegerin (OPG) protein and gene level is improved in vitro; the bone absorption amount of orthodontic bone absorption rat alveolar bone is reduced, the number of alveolar bone osteoclasts is reduced, and the level of rat serum OPG is improved; the secretion of inflammatory factors IL-1beta, IL-6 and TNF-alpha and myeloperoxidase MPO of the orthodontic bone absorption rats is reduced; and the pathological condition of orthodontic bone absorption rat alveolar bone tissue is improved. Therefore, the combined lactobacillus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The invention relates to preparation and application of a high-entropy lithium argyrodite type sulfide solid electrolyte. The structural formula of the high-entropy sulfide electrolyte is Li theta M alpha N beta P1-alpha-beta S 4.5-lambda X lambda Y 1.5, wherein theta is more than 5.32 and less than 6.46, alpha is more than or equal to 0.01 and less than 0.32, beta is more than or equal to 0.01 and less than 0.32, alpha + beta is more than 0 and less than or equal to 0.32, and lambda is more than 0 and less than or equal to 0.5. In the sulfide solid electrolyte prepared by doping elements with different physical properties, the introduction of metal cations can generate additional lithium vacancies, increase the degree of freedom of lithium ion migration and improve the ionic conductivity, and meanwhile, the introduction of soft acid cations can form a stable tetrahedral structure and improve the air stability; the introduction of the inorganic anions can form a stable interface layer in situ at the lithium negative electrode, prevent the contact between the electrolyte and the lithium negative electrode and improve the stability of the negative electrode interface, and the introduction of the halogen anions can adjust the disorder degree of internal atoms and increase the configuration entropy of the material, so that the diffusion energy barrier of lithium ions is reduced, and the ionic conductivity is improved.

The application discloses a kind of antler active peptide and its application in anti-inflammatory, antioxidant and anti-aging, belong to the field of biotechnology.The application utilizes the first screening from antler new active peptide SPLASDLDL, realizes the competitive inhibition to TNFR1 by its specific binding with TNFR1 receptor characteristics.The polypeptide has anti-inflammatory, antioxidant and anti-aging effects by the constructed testicular Sertoli cell aging model.The application successfully solves the technical problems that prior art fails to find competitive inhibition TNFR1 targeting peptide from antler and elucidates its mechanism of action, provides the mechanism of action and scientific basis for developing new anti-inflammatory and anti-aging drugs from natural products.

The invention provides an application of tin as a filler in circuit board manufacturing, a method and a filler, and the filler is used for filling a cavity of a circuit board before lamination and is removed from the circuit board through high-temperature melting or low-temperature powdering after lamination. According to the application of the tin as the filler in manufacturing of the circuit board, on one hand, when the tin is used as the filler, the filler can stably and reliably play a supporting role in the pressing process of the circuit board, and the circuit board is prevented from being deformed in the pressing process; and on the other hand, the filler can be removed more simply and conveniently, and the damage to the circuit board is reduced, so that the filler can be removed more conveniently and reliably. The invention relates to the field of circuit board manufacturing.

The invention provides a granulocyte-macrophage colony stimulating factor antibody and application thereof, and belongs to the technical field of biological medicine. A granulocyte-macrophage colony stimulating factor (GM-CSF) antibody or fragment has high affinity, can effectively block GM-CSF / GM-CSF receptor interaction, and has low immunogenicity. The GM-CSF antibody or fragment can be used for preventing and / or treating diseases caused by human GM-CSF or detecting human GM-CSF protein or diagnosing related diseases caused by the human GM-CSF protein.

Provided are an anti-GITR monoclonal antibody and a humanized antibody thereof, which can be used to prepare a drug used for activating immune response, particularly a related drug for treating cancer.

The invention relates to diagnosis and a kit for autoimmune nervous system diseases. The diagnosis and the kit comprise application of a reagent for detecting an anti-EEF1D autoantibody to preparation of a preparation for diagnosing the autoimmune nervous system diseases in a subject.

The invention discloses a Lactobacillus paracasei strain capable of relieving bone resorption and having an anti-inflammatory effect and a metagen thereof, and belongs to the technical field of microorganisms. The lactobacillus paracasei CCFM1394 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that the expression of MC3T3-E1 cell osteoprotegerin (OPG) is improved in vitro, and meanwhile, the expression of an RUNX gene of MC3T3-E1 is promoted; therefore, the lactobacillus paracasei has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The present invention relates to a specific binding protein targeting PD-L1 and CD73, wherein the specific binding protein is capable of specifically binding to PD-L1 and / or a fragment thereof, and CD73 and / or a fragment thereof. The present invention further relates to use of the specific binding protein in the treatment, prevention and / or diagnosis of diseases such as immune diseases, acute and chronic inflammatory diseases, and tumor diseases.

The present invention discloses a biologically active 1,4-benzoxazinone derivative and a preparation method and application thereof, wherein the biologically active 1,4-benzoxazinone derivative has the structural formula: utilizing the ability of 1,2,3-triazole ring to coordinate with metal ions, wherein the N atom of triazole and heme ferrous iron can form a coordination interaction, and a batch of novel compounds containing triazole are designed. The prepared compounds are tested for inhibiting IDO1 enzyme activity, and it is found that some compounds have an inhibitory effect on IDO1, and also have a good inhibitory effect on some tumor cells, and can reduce some inflammatory indicators at the same time, and can be further used to prepare IDO1 inhibitory drugs, anti-tumor drugs and anti-inflammatory drugs.

The invention discloses an S100A9 inhibitor gel and a preparation method thereof, and the preparation method comprises the following steps: step 1, mixing and uniformly stirring 0.1-5% by weight of a thickening agent, 0.1-5% by weight of a humectant, 0.05-0.5% by weight of a preservative, 0.1-1% by weight of a stabilizer, 0.01-0.2% by weight of a pH regulator and 88.3-99.64% by weight of water to prepare a water-soluble gel matrix; 2, under the conditions that the pressure is 0.08-0.3 MPa and the temperature is 100-126 DEG C, the water-soluble gel matrix prepared in the step 1 is subjected to high-pressure sterilization for 15-30 minutes, and the water-soluble gel matrix is naturally cooled to the room temperature; step 3, adding an inhibitor into the gel matrix cooled in the step 2 according to a preset proportion, and slowly stirring and uniformly mixing to prepare gel; and step 4, subpackaging the gel prepared in the step 3 into aluminum tubes, and filling and sealing to prepare a medicinal gel finished product containing the S100A9 inhibitor for later use. The gel can be directly smeared on injured wounds caused by surgical wounds, burns, scalds, ulcers and the like, wound tissue healing is promoted, healing time is shortened, and the curative effect is good.

This invention relates to the application of fatty acid-binding protein 4 (FABP4) inhibitors in the treatment of heart failure with preserved ejection fraction. Specifically, the application involves the oral administration of the fatty acid-binding protein 4 (FABP4) inhibitor BMS309403 for the prevention and / or treatment of heart failure with preserved ejection fraction.

The present disclosure relates to compositions and methods for preventing tumor escape by reducing immune checkpoint inhibition. In some embodiments, compositions are provided herein that block the interaction between PD-1 and its ligands (e.g., PD-1 and / or PD-L2) while promoting the interaction between PD-1 and cells on which its ligands are expressed. The present disclosure also provides methods for using such compositions.

The present invention relates to the field of biomedicine, and specifically to a polypeptide with a Preso CT domain as a target and its use in the preparation of a neuroprotective drug. The polypeptide has an amino acid sequence as shown below: PKIKETTV. The polypeptide has a good binding ability with the Preso CT domain and can effectively inhibit the apoptosis of primary neuronal cells in the mouse cortex. In addition, the polypeptide can effectively alleviate the anxiety-depressive behavior of chronic traumatic encephalopathy model mice after tail vein injection, proving that it has a neuroprotective effect. After determining that the Preso CT domain can be used as a target for neuroprotection, it can also be used to develop other neuroprotective drugs with the Preso CT domain as a target, which is of great value for medical research and drug development.

The invention discloses pharmaceutical application of a P2Y11 specific inhibitor and a composition containing the P2Y11 specific inhibitor, and belongs to the technical field of biological medicine. The invention discloses application of NF157 in preparation of drugs related to treatment of HD5-promoted pathogenic infection for the first time. In the aspect of pathogen infection treatment, NF157 can specifically inhibit combination of P2Y11 and HD5, so that the effect that HD5 regulates cytoskeleton rearrangement to promote filamentous pseudopod generation is eliminated, and the NF157 becomes a key link for cutting off pathogen infection. By preventing the cells from generating filamentous pseudopod, the NF157 effectively blocks the capturing path of bacteria, and has a remarkable intervention effect on part of pathogens which are lack of adhesion devices and flagellum and are invaded by relying on cell pseudopod capturing.

This invention discloses the pharmaceutical applications of a P2Y11-specific inhibitor and compositions containing it, belonging to the field of biomedical technology. This invention discloses for the first time the use of NF157 in the preparation of drugs related to the treatment of HD5-induced pathogen infection. In combating pathogen infection, NF157 can specifically inhibit the binding of P2Y11 to HD5, thereby eliminating the role of HD5 in regulating cytoskeleton rearrangement and promoting filopodia formation, thus becoming a key link in interrupting pathogen infection. By preventing the formation of filopodia, NF157 effectively blocks the bacterial capture pathway, showing significant intervention effects on some pathogens that lack adhesion devices and flagella and rely on cellular pseudopodia capture for invasion.

This invention belongs to the field of medicine, specifically disclosing a drug-loaded biomimetic nanodecoy based on genetic engineering, its preparation method, and its application. The drug-loaded biomimetic nanodecoy of this invention comprises CCR2-overexpressing nanovesicles, and the hydrophobic regions of the nanovesicles are loaded with curcumin. This invention also provides a method for preparing the drug-loaded biomimetic nanodecoy based on genetic engineering and its application. The overexpressed CCR2 is used to adsorb excess CCL2 to inhibit the binding of macrophages to CCL2, preventing macrophage chemotaxis and subsequent TGF-β production. This inhibits the activation of hepatic stellate cells by removing pro-fibrotic mediators upstream; simultaneously, curcumin is released to block the downstream TGF-β / Smad signaling pathway, thereby inhibiting the activation of hepatic stellate cells.

The invention discloses a Lactobacillus paracasei strain capable of relieving bone resorption and having an anti-inflammatory effect and a metagen thereof, and belongs to the technical field of microorganisms. The invention provides a novel application of the Lactobacillus paracasei CCFM1396 (Lactobacillus paracasei CCFM1396) in the treatment of the orthodontically induced excessive bone resorption, and particularly provides the application of the Lactobacillus paracasei CCFM1396 in the treatment of the orthodontically induced excessive bone resorption. The lactobacillus paracasei provided by the invention can regulate and control osteoblasts to secrete osteoprotegerin (OPG) and improve gene expression of bone morphogenetic protein (BMP), osteoprotegerin (OPG) and osteopontin (OPN). In a rat orthodontic model, the strain disclosed by the invention can effectively relieve bone resorption, inhibit the inflammatory factor level of gingival tissues and protect the stability of periodontal tissues.

The invention relates to the field of biological medicine, in particular to a targeted binding NGF polypeptide and application thereof. The polypeptide has an amino acid sequence as shown in a formula I. The polypeptide provided by the invention has high affinity with the NGF, and can inhibit the combination of the NGF and a receptor thereof, so as to prevent and / or treat diseases mediated by the NGF.

The invention provides a preparation method of nano cobalt hydroxide, belongs to the technical field of preparation of lithium ion battery materials, and solves the problems that an existing nano cobalt hydroxide preparation process is complex, high in requirements for production equipment and unfavorable for large-scale product.The preparation method comprises the steps that a solution A and a solution B are prepared according to three conditions, and a synthetic reaction and aging are conducted after preparation; after aging is finished, washing the prepared cobalt hydroxide slurry; the washed cobalt hydroxide material is dried; and crushing the dried cobalt hydroxide to obtain a nanoscale cobalt hydroxide product. The prepared nanoscale cobalt hydroxide is small in specific surface area, does not need to add a dispersing agent, is simple in raw material and process, is easy to wash, and is easy for industrial production.

The invention relates to the technical field of solar cells, and discloses a novel hole transport material based on delafossite CuBO2-X semiconductor quantum dots and a preparation method of a perovskite solar cell containing the material. The material comprises quantum dots which are formed by CuBO2-X and have the diameter of 1-5 nm and the thickness of 1-10 nm, and a layer of compact thin film is formed by the quantum dots and serves as a hole transport layer of a perovskite solar cell. As the hole transport material has the characteristics of proper energy level structure, high conductivity and the like, extraction and transmission of current carriers are facilitated, in addition, the hole transport material is good in chemical stability and wide in band gap, the hole transport material is applied to a trans-perovskite solar cell as a hole transport layer, the layer can absorb very strong ultraviolet light, and the hole transport material can be applied to the solar cell. Therefore, the perovskite film is effectively prevented from being degraded due to irradiation of strong ultraviolet light, ion migration can be inhibited due to the fact that the interface characteristic is enhanced, the device shows higher stability, and therefore the efficient and stable perovskite solar cell can be obtained.

The invention discloses a bone homeostasis regulating metagen prepared from streptococcus salivarius CCFM1395 and application of the bone homeostasis regulating metagen, and belongs to the technical field of microorganisms. The streptococcus salivarius CCFM1395 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that the expression of MC3T3-E1 cell osteoprotegerin (OPG) is improved in vitro. Therefore, the streptococcus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

This invention provides the application of eugenin in the preparation of drugs for the treatment and / or prevention of inflammatory bowel disease. Using a DSS-induced C57BL / 6J mouse colitis model, this invention found that desulfovibrio flagellin (DVF) promotes intestinal inflammation, while eugenin treatment improves DVF-induced weight loss and inflammation-related parameters such as disease activity index in mice. Further investigation into the specific mechanism of its anti-inflammatory effect revealed that eugenin can act as an inhibitor of the interaction interface between DVF and NLR family apoptosis-inhibiting proteins (NAIP), thereby targeting and inhibiting the sustained activation of the NAIP / NLRC4 inflammasome and pyroptosis in macrophages, reducing the release of inflammatory factors. In conclusion, this traditional Chinese medicine monomer, eugenin, can provide a new approach for the future treatment of inflammatory bowel disease and related diseases.

The invention relates to the technical field of biology, in particular to an anti-thyroid stimulating hormone receptor monoclonal antibody 22B1 and application thereof. The invention discloses a monoclonal antibody 22B1 for resisting a thyroid stimulating hormone receptor. The sequence of the monoclonal antibody 22B1 comprises a heavy chain variable region as shown in SEQ ID NO.8 and a light chain variable region as shown in SEQ ID NO.17; the monoclonal antibody 22B1 has high affinity with TSHR289 protein, can be combined with natural wild type TSHR, has thyroid irritating activity, can competitively inhibit combination of TRAb and TSHR in serum of GD patients, has relatively strong biological activity, can be used for preparation of specific therapeutic drugs for resisting irritating TRAb or development of in-vitro diagnostic kits, and can be used for preparing anti-irritating TRAb. A theoretical basis and a powerful tool are provided for clinical TRAb type detection, and the method can be used for developing specific therapeutic drugs for stimulating TRAb antibodies.

The application discloses a phase change microcapsule composite heat storage material with photocatalytic characteristics and a preparation method thereof. The phase change microcapsule composite heat storage material has a whole core-shell structure, paraffin as a core, crystalline TiO2 with photocatalytic characteristics as a shell wall coated on the surface of the paraffin, and nano-titanium nitride and carbon nanotube composite blended photothermal conversion particles as core-shell modification materials uniformly attached to the surface of the TiO2. The phase change microcapsule composite heat storage material has a stable core-shell structure, full-spectrum solar photothermal conversion capacity, and effectively improves the coating rate, the thermal conductivity and the photocatalytic efficiency, retains the thermal properties of paraffin and inhibits leakage and corrosion.

The present invention relates to the fields of immunology and molecular virology, in particular to the diagnosis, prevention and treatment of coronaviruses (e.g., SARS-CoV-2). Specifically, the present invention relates to single-domain antibodies against coronaviruses, and uses of the single-domain antibodies. The antibodies of the present invention can be used to diagnose, prevent and / or treat coronavirus infections and / or diseases caused by the infections.

The invention discloses application of a reinforcing agent or an inhibitor of MARCKS protein, and belongs to the technical field of medicines. It is proved for the first time that by applying an enhancer of MARCKS and targeting MARCKS protein, the infection capacity of HIV virus particles is inhibited, the neutralizing capacity of a broad-spectrum neutralizing antibody to HIV is enhanced, the limitation of an existing antiviral treatment scheme can be effectively overcome, and a more effective treatment scheme is provided for HIV infection. The MARCKS inhibitor is applied to target MARCKS protein, so that the combination of PD-1 and PD-L1 is inhibited, the killing capability of CTL cells on target cells is enhanced, and the effectiveness of tumor immunotherapy is improved. The content disclosed by the invention shows good potential in treatment of AIDS and malignant tumors, and provides a new strategy for treatment of AIDS and malignant tumors.